Cambridge Design Partnership to collaborate with Stevanto Group on pen-injector for diabetes patients
Cambridge Design Partnership (CDP) will work with the Stevanato Group on a new pen-injector for diabetes patients, with further projects expected to follow.
The companies say they will offer drug delivery solutions to pharmaceutical customers, from first concept to design development, scale-up, regulatory submission and commercial-scale production in all global markets.
CDP, a Toft-based technology and product design partner, will bring its expertise in drug delivery to the partnership.
Headquartered in Padua, Italy, the Stevanato Group has experience in glass containers, tooling, injection moulding and device assembly, and has a global commercial network.
For the initial project, they will create a pen-injector based on the Axis-D technology and intellectual property licensed exclusively from Haselmeier in 2019.
Uri Baruch, CDP’s head of drug delivery, said: “We are delighted to be announcing this partnership. The Stevanato Group is well established in the device field as a leading supplier of cartridges and assembly equipment for pen-injectors.
“It is a pleasure to extend our existing working relationship with them for their pen-injector and to address the needs of patients.”
Paolo Patri, chief technology officer at the Stevanato Group, added: “Our R&D team - with the active support of CDP, an established player in the design and development of drug delivery devices - will offer a competitive pen-injector platform and some customisation options.
“With the resources and experience of both companies, we will provide diabetic patients with a product that is easy-to-use, aesthetically appealing and cost-effective.”
The collaboration follows substantial growth in CDP’s team of healthcare-focused designers and engineers in Toft and at its US base in Raleigh, North Carolina.
“This is another strong vote of confidence in CDP. We look forward to this being the first of many end-to-end projects that we can collaborate on in this new partnership,” said Uri.
Read more
Artificial pancreas app for type 1 diabetes patients launched after University of Cambridge research
